SCHEMBL14359456

SCHEMBL14359456

CC1CN(C(=O)C(O)c2ccccc2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ HPGD P15428 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ PLA2G1B P04054 1/20 0.43
▸ ATG4B Q9Y4P1 1/20 0.43
▸ CES2 O00748 1/20 0.43
▸ CES1 P23141 1/20 0.43
▸ CHRM1 P11229 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NR1I2 O75469 1/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ CHRM2 P08172 1/20 0.41
▸ CHRM4 P08173 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16365588 0.93 PLA2G1B (0.51) LMNAMAPK1MEN1KMT2AHPGD
SCHEMBL14359594 0.87 ACHE (0.50) MAPK1HPGDCHRM1ALDH1A1CHRM3
SCHEMBL20343486 0.80 LMNA (0.44) LMNAMAPK1JAK1CES2CES1
SCHEMBL16365845 0.77 PLA2G1B (0.51) LMNAMEN1KMT2AHPGDPLA2G1B
SCHEMBL12744721 0.76 CHRNB2 (0.60) —
SCHEMBL18390258 0.76 CHRM1 (0.63) CHRM1CYP2D6HSD17B10CHRM2CHRM4
SCHEMBL29522101 0.76 CHRM1 (0.63) CHRM1CYP2D6HSD17B10CHRM2CHRM4
SCHEMBL27780237 0.76 DPP4 (0.46) LMNAMAPK1
SCHEMBL18171456 0.76 DPP4 (0.46) LMNAMAPK1
SCHEMBL18390264 0.73 CHRM1 (0.65) MEN1KMT2ACHRM1ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265289-A1 2-Aminopyrimidine Derivative ASTELLAS PHARMA INC. (JP) 2007-11-15 — — US disclosed
US-20070265289-A1 2-Aminopyrimidine Derivative ASTELLAS PHARMA INC. (JP) 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265289-A1 2-Aminopyrimidine Derivative NFKBIA, IKBKG, NFKB2 LMNA 4358/4885MAPK1 839/4885MEN1 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback